225 Actinium-labeled prostate-specific membrane antigen targeting peptide induces complete response in a metastatic prostate cancer patient.
In: Acta Radiologica Open, Jg. 10 (2021-05-01), Heft 5, S. 1-5
Online
academicJournal
Zugriff:
Targeted radionuclide therapy has emerged as a promising and potentially curative strategy for high-grade prostate cancer. However, limited data are available on efficacy, quality of life, and pretherapeutic biomarkers. Here, we highlight the case of a patient with prostate-specific membrane antigen (PSMA)-positive metastatic castrate-resistant prostate cancer who displayed complete response to 225 Ac-PSMA-617 after having been resistant to standard-of-care therapy, then initially partially responsive but later resistant to subsequent immunotherapy, and resistant to successive 177 Lu-PSMA-617. In addition, the patient's baseline germline mutation likely predisposed him to more aggressive disease. [ABSTRACT FROM AUTHOR]
Copyright of Acta Radiologica Open is the property of Sage Publications, Ltd. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
225 Actinium-labeled prostate-specific membrane antigen targeting peptide induces complete response in a metastatic prostate cancer patient.
|
---|---|
Autor/in / Beteiligte Person: | Aras, Omer ; Harmsen, Stefan ; Ting, Richard ; Sayman, Haluk B |
Link: | |
Zeitschrift: | Acta Radiologica Open, Jg. 10 (2021-05-01), Heft 5, S. 1-5 |
Veröffentlichung: | 2021 |
Medientyp: | academicJournal |
ISSN: | 2058-4601 (print) |
DOI: | 10.1177/20584601211022509 |
Schlagwort: |
|
Sonstiges: |
|